Last updated: April 24, 2026
Eisai Co., Ltd. v. Alkem Laboratories Ltd. (1:19-cv-01213-LPS): Litigation Status, Patent Claims, and Business Implications
What is the case and who are the parties?
- Court / docket: U.S. District Court for the District of Delaware, No. 1:19-cv-01213-LPS.
- Plaintiff: Eisai Co., Ltd.
- Defendant: Alkem Laboratories Ltd.
What is the litigation posture (what has been litigated)?
No complete, accurate docket-linked record of the asserted patents, claim construction, motion outcomes, or final disposition is available from the information provided in this prompt. Under the constraints, a complete litigation summary and analysis cannot be produced without verified specifics.
What does the complaint typically target in this fact pattern (and what you should not infer here)?
This prompt does not include:
- the drug name at issue,
- the Orange Book reference product used in the filing,
- the ANDA filing date or paragraph certification,
- the specific asserted patent numbers,
- or the requested relief.
A litigation summary that guesses at any of these would risk factual error.
Litigation intelligence that can be stated without guessing
Even without the asserted-patent specifics, the business relevance of a Delaware paragraph-IV style case generally centers on:
- timing of injunctive relief tied to patent expiry and manufacturing entry dates,
- expected settlement triggers tied to validity and infringement strength on asserted claims,
- and downstream impacts on market exclusivity and launch sequencing for the generic applicant.
However, the prompt does not provide the necessary case-specific facts to map those levers to this docket.
Actionable decision points for investors and R&D teams
Because the asserted patents and procedural outcomes are not provided, actionable points tied to this case cannot be grounded in record facts. A credible analysis would require at least:
- which patents were asserted,
- what claim types were in play (composition, method, formulation, use, polymorph, etc.),
- whether the court issued claim construction and how it ruled on infringement,
- and whether any patents were found invalid or not infringed.
This prompt does not include those elements, so any “analysis” would be speculative.
Key Takeaways
- The case is identified as Eisai Co., Ltd. v. Alkem Laboratories Ltd., No. 1:19-cv-01213-LPS in the District of Delaware.
- The prompt does not provide the record elements needed for a complete litigation summary: asserted patents, infringement/validity issues, claim construction, motion outcomes, and final disposition.
- No fact-based patent litigation analysis can be completed from the provided information without risking incorrect statements.
FAQs
-
What court and docket number governs this dispute?
U.S. District Court for the District of Delaware, No. 1:19-cv-01213-LPS.
-
Who are the parties?
Eisai Co., Ltd. (plaintiff) and Alkem Laboratories Ltd. (defendant).
-
What patents are at issue?
Not stated in the information provided.
-
Has there been a final judgment or settlement?
Not stated in the information provided.
-
What product is covered by the dispute?
Not stated in the information provided.
References
[1] U.S. District Court, District of Delaware. Eisai Co., Ltd. v. Alkem Laboratories Ltd., No. 1:19-cv-01213-LPS.
